Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

NĚMEC Pavel ZEMANOVÁ Zuzana GREŠLIKOVÁ Henrieta MICHALOVÁ Kyra FILKOVÁ Hana TAJTLOVÁ Jana KRÁLOVÁ Dana KUPSKÁ Renata SMETANA Jan KREJČÍ Marta POUR Luděk ZAHRADOVÁ Lenka SANDECKÁ Viera ADAM Zdeněk BÜCHLER Tomáš ŠPIČKA Ivan GREGORA Evžen KUGLÍK Petr HÁJEK Roman

Year of publication 2010
Type Article in Periodical
Magazine / Source Biology of Blood and Marrow Transplantation
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords Multiple myeloma; 1q21 Gain; Survival; Chromosomal aberrations; Fluorescein in situ hybridization
Description The prognostic significance of 1q21 gain, del(13)(q14), del(17)(p13), t(4;14)(p16.3;q32), and t(11;14)(q13;q32) detected by interphase fluorescein in situ hybridization (FISH) was studied in a cohort of 91 patients with newly diagnosed multiple myeloma (MM). 1q21 gain was detected in 37 of 91 patients (40.7%). In comparison with patients lacking 1q21 gain, patients with 1q21 gain had significantly shorter progression-free survival (PFS) (14.9 versus 27.4 months; P = .044) and worse 4-year overall survival (OS) (40.1% versus 76.2% of patients; P = <.001). PFS or OS were not influenced by the presence or absence of the other studied chromosomal abnormalities. Although the occurrence of 1q21 gain correlated with deletion of 13q14, the presence of 1q21 gain can be considered an independent prognostic factor, as no impact of del(13)(q14) as an isolated chromosomal abnormality on either PFS or OS has been observed. We conclude that 1q21 gain defines a prognostically unfavorable group of MM patients.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.